Lineage to Present at 2024 BIO International Convention

Lineage to Present at 2024 BIO International Convention

 

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company's CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage's novel pipeline of cell therapy transplant programs. The BIO International Convention is the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

 

  About BIO  

 

BIO is the world's largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product, to Fortune 500 multinationals. BIO also represents state and regional biotech associations, service providers to the industry, and academic centers. Our members help foster a healthy economy by creating good-paying, biotechnology jobs. We also host the largest cost-savings program in the life sciences industry, BIO Business Solutions, which saves nearly $700 million in aggregate for 4,500+ companies every year. For more information visit www.bio.org or follow the organization on X/Twitter @ IAmBiotech .

 

  About Lineage Cell Therapeutics, Inc.  

 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell .

 

  

  

  Lineage Cell Therapeutics, Inc. IR  
Ioana C. Hone
( ir@lineagecell.com )
(442) 287-8963

 

  LifeSci Advisors  
Daniel Ferry
( daniel@lifesciadvisors.com )
(617) 430-7576

 

  Russo Partners – Media Relations  
Nic Johnson or David Schull
( Nic.johnson@russopartnersllc.com )
( David.schull@russopartnersllc.com )
(212) 845-4242

 

News Provided by Business Wire via QuoteMedia

LCTX:US
The Conversation (0)
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

 
  •   Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins  
  •  
  •   Clinical Session Expanded to Include Neuralink  
  •  
  •   Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical  
  •  

 

 

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

 
  •   Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program  
  •  
  •   Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit  
  •  
  •   OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting  
  •  
  •   OPC1 Clinical Study Start Up Preparation Underway  
  •  
  •   Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium  
  •  
  •   Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development  
  •  

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

 

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
OpRegen®  Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

 
  •   BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)  
  •  
  •   BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)  
  •  
  •   Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layers observed by optical coherence tomography (OCT) in patients with extensive bleb coverage of the GA lesion  
  •  
  •   Data suggests OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 years following a single administration  
  •  

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit . The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute . The presentation, "OpRegen ® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial," was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.

 

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

 

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

 

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

 

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

 

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Noble Reports on Canada Nickel's Continued Exploration Success at MacDiarmid, Provides Exploration Update

Noble Reports on Canada Nickel's Continued Exploration Success at MacDiarmid, Provides Exploration Update

 

(TheNewswire)

 
       
  Noble Mineral Exploration Inc. 
                
 

  Highlights  

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Finlay Minerals Ltd. engages Investing News Network

Finlay Minerals Ltd. engages Investing News Network

 
 

   VANCOUVER, BC   ,   July 7, 2025   /CNW/ -  finlay minerals ltd.  (TSXV: FYL) (OTCQB: FYMNF) (" Finlay " or the " Company ") reports that it has engaged Dig Media Inc. doing business as Investing News Network ("INN") for investor relations services.

 
 

  Finlay Minerals Ltd. logo (CNW Group/Finlay Minerals Ltd.) 

 

The Company has engaged INN to provide advertising, profile generation, press release syndication, and lead generation through their website. The contract was entered into on March 31, 2025 with a start date of May 30, 2025 for a 12-month period for total costs of $26,275.20 . There are no performance factors contained in the agreement in respect of INN's engagement, and INN will not receive common shares or options of the Company as compensation. INN's engagement is subject to the approval of the TSX Venture Exchange.

 

INN is a private company headquartered in Vancouver, Canada , and is an arms-length organization to the Company. Neither INN nor any of its principals have an interest, directly or indirectly, in the securities of the Company.

 

  About finlay minerals ltd.  

 

Finlay is a TSXV company focused on exploration for base and precious metal deposits with five 100% owned properties in northern British Columbia : the PIL and ATTY properties in the Toodoggone (13,374 hectares ("ha")), the Silver Hope Cu-Ag Property (21,322 ha) and the SAY Cu-Ag & the JJB Cu Properties (41,655 ha) in the Bear Lake Corridor. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries.

 

The PIL and ATTY Properties are fully and sole funded by Freeport-McMoRan through 6-year Earn-In Agreements; the JJB, SAY and Silver Hope 2025 exploration programs are fully funded by Finlay.

 

Finlay trades under the symbol "FYL" on the TSXV and under the symbol "FYMNF" on the OTCQB. For further information and details, please visit the Company's website at www.finlayminerals.com  

 

  On behalf of the Board of Directors,  

 

  Robert F. Brown , P. Eng.
President, Executive Chairman of the Board & Director

 

  Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.  

 

   Forward-Looking Information:    This news release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, corporate plans. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay's proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law.  

 

SOURCE finlay minerals ltd. 

 

 

 

 Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/07/c0723.html  

 
 

 

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
FPX Nickel Receives Multi-Year Area-Based  Permit and Commences 2025 Drilling Activities at Baptiste Nickel Project

FPX Nickel Receives Multi-Year Area-Based Permit and Commences 2025 Drilling Activities at Baptiste Nickel Project

 
 

FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (" FPX " or the " Company ") is pleased to report that it has received a multi-year area-based (" MYAB ") permit from the government of British Columbia to support the renewal of drilling activities at the Baptiste Nickel Project (" Baptiste " or " the Project ") in 2025.  This year's drilling program has commenced successfully, targeting the completion of geomechanical, hydrogeological, and condemnation holes to complement the Project dataset for the feasibility study and the Company's planned entry into the environmental assessment (" EA ") process in the second half of 2025.

 

 

 

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Questcorp Mining Continues Exploration in Advance of Drilling at the La Union Gold & Silver Project in Mexico

Questcorp Mining Continues Exploration in Advance of Drilling at the La Union Gold & Silver Project in Mexico

Questcorp Mining Inc. (CSE: QQQ) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") is pleased to update shareholders on the on-going surface exploration in preparation for drilling at the La Union Gold-Silver Project in Sonora, Mexico. Questcorp has an Option earn a 100% interest from Riverside Resources Inc. in the 2,520 ha (25 km sq) property by making a series of cash payments and share issuance and completing a series of exploration expenditures.

Questcorp President & CEO, Saf Dhillon, stated: "We are pleased with the progress Riverside has made as we complete the preliminary exploration steps, in finalizing our drill targets for the upcoming maiden drill program at La Union. The decades of in country exploration experience that John-Mark and his Riverside team diligently bring to focus at the La Union project is very evident as they continue to further de-risk the up-coming 1,500 metre drill program."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×